The influence of chemotherapy-associated sinusoidal dilatation on short-term outcome after partial hepatectomy for colorectal liver metastases: A systematic review with meta-analysis

Surgical Oncology

Volumn 25, Issue 3, 2016, Pages 298-307

  Van Mierlo, Kim M C ^a   Zhao, Junfang ^a   Kleijnen, Jos ^b,c   Rensen, Sander S ^a   Schaap, Frank G ^a   Dejong, Cornelis H C ^a,d   Olde Damink, Steven W M ^a,e  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KLEIJNEN SYSTEMATIC REVIEWS LTD   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy associated liver injury; Partial hepatectomy; Postoperative liver failure; Sinusoidal dilatation; Sinusoidal obstruction syndrome; SOS

Indexed keywords

BILIRUBIN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ARTIFICIAL EMBOLIZATION; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CINAHL; COLORECTAL LIVER METASTASIS; DILATATION; HOSPITALIZATION; HUMAN; LIVER FAILURE; META ANALYSIS; MORBIDITY; OUTCOME ASSESSMENT; PARTIAL HEPATECTOMY; PORTAL VEIN EMBOLIZATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; QUALITY CONTROL; REVIEW; SHORT TERM SURVIVAL; SINUSOIDAL DILATATION; SURGICAL MORTALITY; SYSTEMATIC REVIEW; ADULT; CHEMICAL AND DRUG INDUCED LIVER INJURY; COLORECTAL NEOPLASMS; DILATATION, PATHOLOGIC; LIVER NEOPLASMS; LIVER RESECTION; PATHOLOGY; PROGNOSIS; SECONDARY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COLORECTAL NEOPLASMS; DILATATION, PATHOLOGIC; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; PROGNOSIS;

EID: 84975230583     PISSN: 09607404     EISSN: 18793320     Source Type: Journal    
DOI: 10.1016/j.suronc.2016.05.030     Document Type: Article

References (70)

1. L. Rubbia-Brandt, V. Audard, P. Sartoretti, A.D. Roth, C. Brezault, M. Le Charpentier, B. Dousset, P. Morel, O. Soubrane, S. Chaussade, G. Mentha, and B. Terris Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer Ann. Oncol. 15 3 2004 460 466
2. L. Rubbia-Brandt, G.Y. Lauwers, H. Wang, P.E. Majno, K. Tanabe, A.X. Zhu, C. Brezault, O. Soubrane, E.K. Abdalla, J.-N.N. Vauthey, G. Mentha, and B. Terris Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis Histopathology 56 4 2010 430 439
3. S.M. Robinson, C.H. Wilson, A.D. Burt, D.M. Manas, and S.A. White Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis Ann. Surg. Oncol. 19 13 2012 4287 4299
4. V.W. Lam, C. Spiro, J.M. Laurence, E. Johnston, M.J. Hollands, H.C. Pleass, and A.J. Richardson A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases Ann. Surg. Oncol. 19 4 2012 1292 1301
5. Y. Seium, R. Stupp, T. Ruhstaller, P. Gervaz, G. Mentha, M. Philippe, A. Allal, C. Trembleau, J. Bauer, R. Morant, and A.D. Roth Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study Ann. Oncol. 16 5 2005 762 766
6. R. Adam, V. Delvart, G. Pascal, A. Valeanu, D. Castaing, D. Azoulay, S. Giacchetti, B. Paule, F. Kunstlinger, O. Ghemard, F. Levi, and H. Bismuth Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival Ann. Surg. 240 4 2004 644 657 discussion 657-658
7. J. Agostini, S. Benoist, M. Seman, C. Julie, S. Imbeaud, F. Letourneur, N. Cagnard, P. Rougier, A. Brouquet, J. Zucman-Rossi, and P. Laurent-Puig Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation J. Hepatol. 56 4 2012 869 876
8. K. Nakamura, E. Hatano, A. Miyagawa-Hayashino, M. Okuno, Y. Koyama, M. Narita, S. Seo, K. Taura, and S. Uemoto Soluble thrombomodulin attenuates sinusoidal obstruction syndrome in rat through suppression of high mobility group box 1 Liver Int. 34 10 2014 1473 1487
9. S.M. Robinson, J. Mann, A. Vasilaki, J. Mathers, A.D. Burt, F. Oakley, S.A. White, and D.A. Mann Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model J. Hepatol. 59 2 2013 318 326
10. X. Wang, G.C. Kanel, and L.D. DeLeve Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat Hepatology 31 2 2000 428 434
11. L.D. DeLeve, Y. Ito, N.W. Bethea, M.K. McCuskey, X. Wang, and R.S. McCuskey Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome Am. J. Physiol. Gastrointest. Liver Physiol. 284 6 2003 G1045 G1052
12. T. Ezzat, M.A. van den Broek, N. Davies, C.H. Dejong, A. Bast, M. Malago, D.K. Dhar, and S.W. Olde Damink The flavonoid monoHER prevents monocrotaline-induced hepatic sinusoidal injury in rats J. Surg. Oncol. 106 1 2012 72 78
13. C.Q. Fan, and J.M. Crawford Sinusoidal obstruction syndrome (hepatic veno-occlusive disease) J. Clin. Exp. Hepatol. 4 4 2014 332 346
14. L.D. DeLeve, R.S. McCuskey, X. Wang, L. Hu, M.K. McCuskey, R.B. Epstein, and G.C. Kanel Characterization of a reproducible rat model of hepatic veno-occlusive disease Hepatology 29 6 1999 1779 1791
15. G. Mentha, S. Terraz, P. Morel, A. Andres, E. Giostra, A. Roth, L. Rubbia-Brandt, and P. Majno Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases Br. J. Surg. 96 1 2009 95 103
16. M.J. Overman, D.M. Maru, C. Charnsangavej, E.M. Loyer, H. Wang, P. Pathak, C. Eng, P.M. Hoff, J.N. Vauthey, R.A. Wolff, and S. Kopetz Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury J. Clin. Oncol. 28 15 2010 2549 2555
17. R. Arotcarena, V. Cales, P. Berthelemy, Y. Parent, M. Malet, F. Etcharry, S. Ferrari, and A. Pariente Severe sinusoidal lesions: a serious and overlooked complication of oxaliplatin-containing chemotherapy? Gastroenterol. Clin. Biol. 30 11 2006 1313 1316
18. J.H. Slade, M.L. Alattar, D.R. Fogelman, M.J. Overman, A. Agarwal, D.M. Maru, R.L. Coulson, C. Charnsangavej, J.N. Vauthey, R.A. Wolff, and S. Kopetz Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury Clin. Colorectal Cancer 8 4 2009 225 230
19. K. Imai, Y. Emi, K.I. Iyama, T. Beppu, Y. Ogata, Y. Kakeji, H. Samura, E. Oki, Y. Akagi, Y. Maehara, H. Baba Kyusyu Study Group of Clinical Cancer ancillary Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome Eur. J. Surg. Oncol. 40 5 2014 559 566
20. H. Nakano, E. Oussoultzoglou, E. Rosso, S. Casnedi, M.P. Chenard-Neu, P. Dufour, P. Bachellier, and D. Jaeck Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy Ann. Surg. 247 1 2008 118 124
21. D. Tamandl, M. Klinger, S. Eipeldauer, B. Herberger, K. Kaczirek, B. Gruenberger, and T. Gruenberger Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy Ann. Surg. Oncol. 18 2 2011 421 430
22. J. Gomez-Ramirez, E. Martin-Perez, C.G. Amat, I.G. Sanz, E. Bermejo, A. Rodriguez, and E. Larranaga Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases Cir. Esp. 88 6 2010 404 412
23. T. Takamoto, T. Hashimoto, K. Sano, Y. Maruyama, K. Inoue, S. Ogata, T. Takemura, N. Kokudo, and M. Makuuchi Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis Ann. Surg. Oncol. 17 10 2010 2747 2755
24. S. Kandutsch, M. Klinger, S. Hacker, F. Wrba, B. Gruenberger, and T. Gruenberger Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases Eur. J. Surg. Oncol. 34 11 2008 1231 1236
25. H. Komori, T. Beppu, Y. Baba, K. Horino, C. Imsung, T. Masuda, H. Hayashi, H. Okabe, R. Ootao, M. Watanabe, H. Takamori, K. Iyama, and H. Baba Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients Int. J. Clin. Oncol. 15 3 2010 263 270
26. F. Makowiec, S. Mohrle, H. Neeff, O. Drognitz, G. Illerhaus, O.G. Opitz, U.T. Hopt, and A. zur Hausen Chemotherapy, liver injury, and postoperative complications in colorectal liver metastases J. Gastrointest. Surg. 15 1 2011 153 164
27. T.M. Pawlik, K. Olino, A.L. Gleisner, M. Torbenson, R. Schulick, and M.A. Choti Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome J. Gastrointest. Surg. 11 7 2007 860 868
28. A. Sahajpal, C.M. Vollmer, E. Dixon, E.K. Chan, A. Wei, M.S. Cattral, B.R. Taylor, D.R. Grant, P.D. Greig, and S. Gallinger Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes J. Surg. Oncol. 95 1 2007 22 27
29. D. Takeda, H. Nitta, T. Takahara, Y. Hasegawa, N. Itou, and G. Wakabayashi Effect of preoperative chemotherapy on postoperative liver regeneration following hepatic resection as estimated by liver volume World J. Surg. Oncol. 11 2013 65
30. J.A. Hayden, M.E. Tougas, R. Riley, R. Iles, and T. Pincus Individual recovery expectations and prognosis of outcomes in non-specific low back pain: prognostic factor exemplar review (Protocol) Cochrane Database Syst. Rev. Issue 9 2014
31. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann. Intern. Med. 151 4 2009 264 269 W64
32. D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe, S.B. Thacker, and M. Grp Meta-analysis of observational studies in epidemiology - a proposal for reporting JAMA 283 15 2000 2008 2012
33. M. Narita, E. Oussoultzoglou, M.P. Chenard, E. Rosso, S. Casnedi, P. Pessaux, P. Bachellier, and D. Jaeck Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization Surg. Today 41 1 2011 7 17
34. CADTH, Canadian Agency for Drugs and Technologies in Health CADTH Peer Review Checklist for Search Strategies 2013 3pp.
35. D. Dindo, N. Demartines, and P.A. Clavien Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann. Surg. 240 2 2004 205 213
36. S. Balzan, J. Belghiti, O. Farges, S. Ogata, A. Sauvanet, D. Delefosse, and F. Durand The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy Ann. Surg. 242 6 2005 824 828 discussion 828-9
37. J.T. Mullen, D. Ribero, S.K. Reddy, M. Donadon, D. Zorzi, S. Gautam, E.K. Abdalla, S.A. Curley, L. Capussotti, B.M. Clary, and J.N. Vauthey Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy J. Am. Coll. Surg. 204 5 2007 854 862 discussion 862-4
38. N.N. Rahbari, O.J. Garden, R. Padbury, M. Brooke-Smith, M. Crawford, R. Adam, M. Koch, M. Makuuchi, R.P. Dematteo, C. Christophi, S. Banting, V. Usatoff, M. Nagino, G. Maddern, T.J. Hugh, J.N. Vauthey, P. Greig, M. Rees, Y. Yokoyama, S.T. Fan, Y. Nimura, J. Figueras, L. Capussotti, M.W. Buchler, and J. Weitz Posthepatectomy liver failure: a definition and grading by the international study group of liver surgery (ISGLS) Surgery 149 5 2011 713 724
39. M.A. van den Broek, R.M. van Dam, G.J. van Breukelen, M.H. Bemelmans, E. Oussoultzoglou, P. Pessaux, C.H. Dejong, N. Freemantle, and S.W. Olde Damink Development of a composite endpoint for randomized controlled trials in liver surgery Br. J. Surg. 98 8 2011 1138 1145
40. J.A. Hayden, P. Cote, and C. Bombardier Evaluation of the quality of prognosis studies in systematic reviews Ann. Intern. Med. 144 6 2006 427 437
41. J.A. Hayden, D.A. van der Windt, J.L. Cartwright, P. Cote, and C. Bombardier Assessing bias in studies of prognostic factors Ann. Intern. Med. 158 4 2013 280 286
42. P. Davis, J. Hayden, J. Springer, J. Bailey, M. Molinari, and P. Johnson Prognostic factors for morbidity and mortality in elderly patients undergoing acute gastrointestinal surgery: a systematic review Can. J. Surg. 57 2 2014 E44 E52
43. M.M. Aloysius, A.M. Zaitoun, I.J. Beckingham, K.R. Neal, G.P. Aithal, E.M. Bessell, and D.N. Lobo The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study Virchows Arch. 451 5 2007 943 948
44. A. Brouquet, S. Benoist, C. Julie, C. Penna, A. Beauchet, P. Rougier, and B. Nordlinger Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases Surgery 145 4 2009 362 371
45. C. Hubert, C. Fervaille, C. Sempoux, Y. Horsmans, Y. Humblet, J.P. Machiels, F. Zech, A. Ceratti, and J.F. Gigot Prevalence and clinical relevance of pathological hepatic changes occurring after neoadjuvant chemotherapy for colorectal liver metastases Surgery 147 2 2010 185 194
46. M. Karoui, C. Penna, M. Amin-Hashem, E. Mitry, S. Benoist, B. Franc, P. Rougier, and B. Nordlinger Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases Ann. Surg. 243 1 2006 1 7
47. Y. Kishi, D. Zorzi, C.M. Contreras, D.M. Maru, S. Kopetz, D. Ribero, M. Motta, N. Ravarino, M. Risio, S.A. Curley, E.K. Abdalla, L. Capussotti, and J.N. Vauthey Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases Ann. Surg. Oncol. 17 11 2010 2870 2876
48. K. Miura, H. Nakano, J. Sakurai, S. Kobayashi, S. Koizumi, T. Arai, T. Shimamura, R. Makizumi, K. Yamada, N. Miyajima, T. Otsubo, and J. Koike Splenomegaly in FOLFOX-naive stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy Int. J. Clin. Oncol. 16 3 2011 257 263
49. M. Narita, E. Oussoultzoglou, P. Fuchshuber, P. Pessaux, M.P. Chenard, E. Rosso, C. Nobili, D. Jaeck, and P. Bachellier What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy? Ann. Surg. Oncol. 19 8 2012 2526 2538
50. E. Nguyen-Khac, C. Lobry, D. Chatelain, D. Fuks, J.P. Joly, M. Brevet, B. Tramier, C. Mouly, V. Hautefeuille, B. Chauffert, and J.M. Regimbeau A reappraisal of chemotherapy-induced liver injury in colorectal liver metastases before the era of antiangiogenics Int. J. Hepatol. 2013 2013 314868
51. P. Pessaux, E. Marzano, S. Casnedi, P. Bachellier, D. Jaeck, and M.P. Chenard Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study World J. Surg. 34 11 2010 2765 2772
52. P. Pessaux, F. Panaro, S. Casnedi, I. Zeca, E. Marzano, P. Bachellier, D. Jaeck, and M.P. Chenard Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study Eur. J. Surg. Oncol. 36 6 2010 575 582
53. O. Soubrane, A. Brouquet, S. Zalinski, B. Terris, C. Brezault, V. Mallet, F. Goldwasser, and O. Scatton Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome Ann. Surg. 251 3 2010 454 460
54. A.E. van der Pool, H.A. Marsman, J. Verheij, F.J. Ten Kate, A.M. Eggermont, J.N. Ijzermans, and C. Verhoef Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases J. Surg. Oncol. 106 7 2012 892 897
55. J.N. Vauthey, T.M. Pawlik, D. Ribero, T.T. Wu, D. Zorzi, P.M. Hoff, H.Q. Xiong, C. Eng, G.Y. Lauwers, M. Mino-Kenudson, M. Risio, A. Muratore, L. Capussotti, S.A. Curley, and E.K. Abdalla Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases J. Clin. Oncol. 24 13 2006 2065 2072
56. L. Vigano, N. Ravarino, A. Ferrero, M. Motta, B. Torchio, and L. Capussotti Prospective evaluation of accuracy of liver biopsy findings in the identification of chemotherapy-associated liver injuries Arch. Surg. 147 12 2012 1085 1091
57. P.S. Wolf, J.O. Park, F. Bao, P.J. Allen, R.P. DeMatteo, Y. Fong, W.R. Jarnagin, T.P. Kingham, M. Gonen, N. Kemeny, J. Shia, and M.I. D'Angelica Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience J. Am. Coll. Surg. 216 1 2013 41 49
58. A. Iorio, F.A. Spencer, M. Falavigna, C. Alba, E. Lang, B. Burnand, T. McGinn, J. Hayden, K. Williams, B. Shea, R. Wolff, T. Kujpers, P. Perel, P.O. Vandvik, P. Glasziou, H. Schunemann, and G. Guyatt Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients BMJ 350 2015 h870
59. A. Huguet, J.A. Hayden, J. Stinson, P.J. McGrath, C.T. Chambers, M.E. Tougas, and L. Wozney Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework Syst. Rev. 2 2013 71
60. S. Stremitzer, J. Stift, J. Singh, P. Starlinger, B. Gruenberger, D. Tamandl, and T. Gruenberger Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases Eur. J. Surg. Oncol. 41 7 2015 868 874
61. D. Ribero, H. Wang, M. Donadon, D. Zorzi, M.B. Thomas, C. Eng, D.Z. Chang, S.A. Curley, E.K. Abdalla, L.M. Ellis, and J.N. Vauthey Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases Cancer 110 12 2007 2761 2767
62. P. Economopoulou, A. Kotsakis, I. Kapiris, and N. Kentepozidis Cancer therapy and cardiovascular risk: focus on bevacizumab Cancer Manag. Res. 7 2015 133 143
63. Z.V. Varga, P. Ferdinandy, L. Liaudet, and P. Pacher Drug-induced mitochondrial dysfunction and cardiotoxicity Am. J. Physiol. Heart Circ. Physiol. 309 9 2015 H1453 H1467
64. B. Aussilhou, S. Dokmak, S. Faivre, V. Paradis, V. Vilgrain, and J. Belghiti Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab Ann. Surg. Oncol. 16 6 2009 1553 1559
65. B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, F. Herbst, and T. Gruenberger Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J. Clin. Oncol. 26 11 2008 1830 1835
66. C.H. Dejong Vascular reconstruction combined with liver resection for malignant tumours Br. J. Surg. 100 13 2013 1776
67. S.K. Reddy, T.M. Pawlik, D. Zorzi, A.L. Gleisner, D. Ribero, L. Assumpcao, A.S. Barbas, E.K. Abdalla, M.A. Choti, J.N. Vauthey, K.A. Ludwig, C.R. Mantyh, M.A. Morse, and B.M. Clary Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis Ann. Surg. Oncol. 14 12 2007 3481 3491
68. K.P. van Lienden, J.W. van den Esschert, W. de Graaf, S. Bipat, J.S. Lameris, T.M. van Gulik, and O.M. van Delden Portal vein embolization before liver resection: a systematic review Cardiovasc. Interv. Radiol. 36 1 2013 25 34
69. J.N. Vauthey, A. Chaoui, K.A. Do, M.M. Bilimoria, M.J. Fenstermacher, C. Charnsangavej, M. Hicks, G. Alsfasser, G. Lauwers, I.F. Hawkins, and J. Caridi Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations Surgery 127 5 2000 512 519
70. R.D. Riley, P.C. Lambert, and G. Abo-Zaid Meta-analysis of individual participant data: rationale, conduct, and reporting BMJ 340 2010 c221